公开(公告)号：US20200171092A1

公开(公告)日：2020-06-04

申请号：US16620655

申请日：2018-05-08

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Hayato Kurata ,  Kotoe Tamada ,  Hiroyuki Nishida

IPC: A61K35/28 ,  A61K9/14 ,  A61K38/20 ,  A61K38/18 ,  A61K38/17 ,  A61P9/10

Abstract: The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.

公开(公告)号：US20190255116A1

公开(公告)日：2019-08-22

申请号：US16343330

申请日：2017-10-13

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Kotoe Tamada

IPC: A61K35/28 ,  A61K9/06 ,  A61K38/48 ,  A61K38/36 ,  A61K9/08 ,  A61P9/10

Abstract: The present invention addresses the problem of providing a disease-treating agent which exerts an excellent effect in treating diseases requiring an emergency surgery such as heart failure and which is efficacious at a certain level for a large number of patients. The present invention pertains to a kit for preparing a disease-treating agent, said kit comprising a) a fibrinogen solution, b) a thrombin solution and c) mesenchymal stem cells, in separate forms respectively. It is preferred that c) the mesenchymal stem cells are allogeneic to a subject to be treated. Also, the present invention pertains to a kit for preparing a disease-treating agent, said kit being to be used by, when in use, suspending c) the mesenchymal stem cells in either a) the fibrinogen solution or b) the thrombin solution, and then spraying the cell suspension thus obtained directly to a disease site substantially simultaneously with either b) the thrombin solution or a) the fibrinogen solution that is not used in the suspending step.

公开(公告)号：US20230032293A1

公开(公告)日：2023-02-02

申请号：US17881413

申请日：2022-08-04

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Kotoe Tamada

IPC: A61K35/28 ,  A61P9/10 ,  A61K9/06 ,  A61K9/08 ,  A61K38/36 ,  A61K38/48 ,  A61K9/12 ,  A61K9/10 ,  A61P9/00 ,  A61K38/00 ,  A61P27/02 ,  A61P43/00

Abstract: Methods are described for treating a heart disease, comprising suspending c) mesenchymal stem cells in either a) a fibrinogen solution or b) a thrombin solution, thereby obtaining a cell suspension, and directly spraying the cell suspension on a disease site substantially at the same time with the other of a) the fibrinogen solution or b) the thrombin solution that is not used in the suspending.

公开(公告)号：US12226436B2

公开(公告)日：2025-02-18

申请号：US16071123

申请日：2017-01-18

Applicant: ROHTO PHARMACEUTICAL CO., LTD

Inventor： Daisuke Kajita ,  Satsuki Fukushima ,  Shigeru Miyagawa ,  Yoshiki Sawa

IPC: A61K35/28 ,  A61K35/35 ,  A61K35/51 ,  A61K35/545

Abstract: It has been found that a cell cluster obtained by causing just isolated cells to adhere to each other secretes adiponectin after transplantation to the heart, and thereby has an excellent therapeutic effect on heart disease.

公开(公告)号：US12084683B2

公开(公告)日：2024-09-10

申请号：US16702755

申请日：2019-12-04

Applicant: TERUMO KABUSHIKI KAISHA ,  OSAKA UNIVERSITY

Inventor： Fumiya Ohashi ,  Hiroko Iseoka ,  Yoshiki Sawa ,  Shigeru Miyagawa

IPC: C12N5/077 ,  A61K35/34 ,  C12N5/00 ,  C12N5/071 ,  C12N5/073 ,  C12N5/0735

CPC classification number: C12N5/0657 ,  A61K35/34 ,  C12N5/0093 ,  C12N5/0602 ,  C12N5/0603 ,  C12N5/0606 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/998 ,  C12N2506/45

Abstract: A method for producing a cell culture containing desired cells is provided. The desired cells are induced to be differentiated from pluripotent stem cells. The method includes seeding a cell population by dispersing embryoid bodies obtained by inducing differentiation from the pluripotent stem cells to the desired cells. The embryoid bodies are dispersed at a density reaching confluence or higher.

公开(公告)号：US11441115B2

公开(公告)日：2022-09-13

申请号：US17042301

申请日：2019-03-12

Applicant: DAI NIPPON PRINTING CO., LTD. ,  OSAKA UNIVERSITY ,  TERUMO KABUSHIKI KAISHA

Inventor： Taro Nagai ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Kenji Oyama

IPC: C12M1/00 ,  C12M1/22 ,  C12M1/34 ,  C12M1/38 ,  C12M3/00 ,  C12M3/06 ,  C12M1/02 ,  C12M1/36

Abstract: When detachment of a cell sheet from a culture dish has started at an unintended timing, immediately detach the cell sheet from the culture dish while preventing generation of wrinkles and the like in the cell sheet. A cell culture device captures an image of cells in the culture dish, and controls a cooling mechanism and a shaking mechanism based on the image so as to shake the cells while cooling them.

公开(公告)号：US20220272963A1

公开(公告)日：2022-09-01

申请号：US17664194

申请日：2022-05-19

Applicant: Saraya Co., Ltd. ,  Osaka University

Inventor： Asuka Nogami ,  Motoki Tatsumi ,  Nanase Ishii ,  Mizuyuki Ryu ,  Yoshihiko Hirata ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Atsuhiro Saito ,  Hirotatsu Ohkawara

IPC: A01N1/02 ,  C12N1/04 ,  C12N5/0775

Abstract: A cell cryopreservation method including adding a 1 volume % of a composition comprising 0.01 wt % to 20 wt % of a sophorose lipid to cells in a cell culture medium just before or up to 6 hours before cryopreserving the cells; and cryopreserving the cell culture medium, wherein the composition improves cell viability after cryopreservation compared to cells that are cryopreserved with a similar composition that does not contain the sophorose lipid.

公开(公告)号：US20200045955A1

公开(公告)日：2020-02-13

申请号：US16482236

申请日：2018-01-30

Applicant: Saraya Co., Ltd. ,  Osaka University

Inventor： Asuka Nogami ,  Motoki Tatsumi ,  Nanase Ishii ,  Mizuyuki Ryu ,  Yoshihiko Hirata ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Atsuhiro Saito ,  Hirotatsu Ohkawara

IPC: A01N1/02 ,  C12N1/04 ,  C12N5/0775

Abstract: This composition can be easily added when cryopreserving cells and improves cell viability. 1 volume % of the composition containing 0.01 wt % to 20 wt % of a sophorose lipid is added just before or up to 6 hours before cryopreservation and cells are stored. This composition can improve cryopreservation cell viability as it reduces freezing damage to cells. With this composition, cells can be stored without using DMSO and blood serum. This is a simple and inexpensive storage method as it does not require fine control of the freezing rate during cell cryopreservation.

公开(公告)号：US20170335284A1

公开(公告)日：2017-11-23

申请号：US15523746

申请日：2015-11-06

Applicant: Osaka University

Inventor： Shigeo Masuda ,  Nagako Sougawa ,  Satsuki Fukushima ,  Shigeru Miyagawa ,  Yoshiki Sawa

IPC: C12N5/077 ,  A61K35/33 ,  C12N5/00

CPC classification number: C12N5/0656 ,  A61K35/12 ,  A61K35/33 ,  A61K35/545 ,  C12N5/00 ,  C12N5/0081 ,  C12N5/0657 ,  C12N5/10 ,  C12N2501/25 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/45

Abstract: Provided is a cell population comprising differentiated cells obtainable by inducing differentiation of pluripotent stem cells, wherein the content ratio of undifferentiated pluripotent stem cells is 0.2% or less.

公开(公告)号：US11969459B2

公开(公告)日：2024-04-30

申请号：US16477878

申请日：2018-01-26

Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

Inventor： Katsuto Tamai ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Takashi Kido ,  Takasumi Goto ,  Takehiko Yamazaki

IPC: A61K38/00 ,  A61K38/19 ,  A61P9/10 ,  C07K14/00

CPC classification number: A61K38/19 ,  A61P9/10

Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and/or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.